Announcements Trials
Browse Landscape

Phase

Phase 3 5Phase 4 3Phase 1/2 2Phase 2 1

Status

Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Lymphoid 1

Conditions

Virus Diseases 1Lymphoma 1Infections 1Epstein-Barr Virus Infections 1

Interventions

Cyclophosphamide 250Radiotherapy 172pembrolizumab 154Carboplatin 146Gemcitabine 139Nivolumab 135Paclitaxel 129Dexamethasone 118Cisplatin 118fludarabine 115Rituximab 104Lenalidomide 103Bevacizumab 99Docetaxel 97Capecitabine 97fludarabine phosphate 92Temozolomide 89Cytarabine 89Oxaliplatin 87Etoposide 82Filgrastim 77Irinotecan 73Doxorubicin 73venetoclax 70Peripheral Blood Stem Cell Transplantation 68Fluorouracil 68Radiosurgery 66Melphalan 66Everolimus 66Bortezomib 66

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × OTHER × Tenofovir × Clear all
NCT07133776 2025-08-21

Application of PD-1 Inhibitors Combined With Tenofovir, Chidamide and Lenalidomide in the Treatment of EBV-associated Diseases.

The Affiliated Hospital of Xuzhou Medical University

Phase 1/2 Not yet recruiting
30 enrolled

Infections, Epstein-Barr Virus Infections

NCT01528865 2016-03-11

Safety & Efficacy of Lamivudine & Tenofovir to Lower Plasma Level of Viral RNA in Lymphoma

University of Michigan Rogel Cancer Center

Phase 1/2 Withdrawn
Lymphoid

Lymphoma, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡